129 related articles for article (PubMed ID: 24746411)
1. Taste acceptability of pulverized brand-name and generic drugs containing amlodipine or candesartan.
Uestuener P; Ferrarini A; Santi M; Mardegan C; Bianchetti MG; Simonetti GD; Milani GP; Lava SA
Int J Pharm; 2014 Jul; 468(1-2):196-8. PubMed ID: 24746411
[TBL] [Abstract][Full Text] [Related]
2. What can we do to make antihypertensive medications taste better for children?
Ferrarini A; Bianchetti AA; Fossali EF; Faré PB; Simonetti GD; Lava SA; Bianchetti MG
Int J Pharm; 2013 Nov; 457(1):333-6. PubMed ID: 23906666
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
4. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
Frampton JE; Scott LJ
Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
[TBL] [Abstract][Full Text] [Related]
5. Palatability of angiotensin II antagonists among nephropathic children.
Meier CM; Simonetti GD; Ghiglia S; Fossali E; Salice P; Limoni C; Bianchetti MG;
Br J Clin Pharmacol; 2007 May; 63(5):628-31. PubMed ID: 17302913
[TBL] [Abstract][Full Text] [Related]
6. Superior palatability of crushed lercanidipine compared with amlodipine among children.
Milani G; Ragazzi M; Simonetti GD; Ramelli GP; Rizzi M; Bianchetti MG; Fossali EF
Br J Clin Pharmacol; 2010 Feb; 69(2):204-6. PubMed ID: 20233185
[TBL] [Abstract][Full Text] [Related]
7. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
8. Palatability of crushed ß-blockers, converting enzyme inhibitors and thiazides.
Zgraggen L; Faré PB; Lava SA; Simonetti GD; Fossali EF; Amoruso C; Bianchetti MG
J Clin Pharm Ther; 2012 Oct; 37(5):544-6. PubMed ID: 22486159
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
Koyanagi R; Hagiwara N; Yamaguchi J; Kawada-Watanabe E; Haruta S; Takagi A; Ogawa H;
J Cardiol; 2013 Oct; 62(4):217-23. PubMed ID: 23778009
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants.
Kim JH; Song JH; Kim M; Hong JH; Sunwoo J; Jung JG
Adv Ther; 2024 Jul; 41(7):2808-2825. PubMed ID: 38771476
[TBL] [Abstract][Full Text] [Related]
12. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
Deeks ED
Am J Cardiovasc Drugs; 2009; 9(6):411-8. PubMed ID: 19929039
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan/amlodipine: single-pill combination in hypertension.
Moen MD
Am J Cardiovasc Drugs; 2010; 10(6):401-12. PubMed ID: 21090832
[TBL] [Abstract][Full Text] [Related]
14. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
Brachmann J; Ansari A; Mahla G; Handrock R; Klebs S
Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
[TBL] [Abstract][Full Text] [Related]
15. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
Ishimitsu T; Kobayashi T; Honda T; Takahashi M; Minami J; Ohta S; Inada H; Yoshii M; Ono H; Matsuoka H
Hypertens Res; 2005 Apr; 28(4):351-9. PubMed ID: 16138566
[TBL] [Abstract][Full Text] [Related]
18. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
Baser O; Andrews LM; Wang L; Xie L
J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
[TBL] [Abstract][Full Text] [Related]
19. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
Hermida RC; Ayala DE; Fontao MJ; Mojón A; Fernández JR
Chronobiol Int; 2010 Jul; 27(6):1287-303. PubMed ID: 20653455
[TBL] [Abstract][Full Text] [Related]
20. No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects.
Kim JR; Kim S; Huh W; Ko JW
Drug Des Devel Ther; 2018; 12():2475-2483. PubMed ID: 30127595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
